trending Market Intelligence /marketintelligence/en/news-insights/trending/fkdfcsehcv7jgxiibjkbdg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

MediciNova's ALS treatment orphan-drug designated in Europe

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


MediciNova's ALS treatment orphan-drug designated in Europe

The European Commission designated as an orphan drug MediciNova Inc.'s MN-166 treatment for amyotrophic lateral sclerosis, or ALS.

The development offers potential benefits including protocol assistance, fee reductions and a 10-year market exclusivity once the medicine is introduced in the European market.

The drug is also designated as an orphan drug for ALS in the U.S. and is marketed in Japan and Korea to treat post-stroke complications and bronchial asthma.